Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun

Title:Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun

Volume: 23 Issue: 10

Author(s): Charles Faselis*, Chrysoula Boutari, Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos and Peter Kokkinos

Affiliation:

• VA Medical Center, 50 Irving Street, NW, Washington, DC 20422,United States

Keywords: LCZ696, neprilysin, hypertension, heart failure, finerenone, mineralocorticoid receptor antagonists, albuminuria, diabetic kidney disease.

Abstract: Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions.

Methods: This review aims to present the pathophysiological basis for the use of these two novel drugs, critically discuss available clinical data, and provide future perspectives.

Results: LCZ696 seems a very promising antihypertensive agent, that additionally generates clinically meaningful benefits in patients with heart failure with reduced injection fraction and raises expectations for the management of patients with heart failure with preserved ejection fraction. Finerenone aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria. First available data are very promising for the efficacy of the drug, while it provides a better safety profile than current mineralocorticoid antagonists.

Conclusion: LCZ696 and finerenone are two novel drugs for the management of arterial hypertension and heart failure. First available data point toward important clinical benefits from their use. Future large trials further investigating the cardiovascular profile of these agents will establish the use of these drugs.

Cite this article as:

Faselis Charles*, Boutari Chrysoula, Doumas Michael, Imprialos Konstantinos, Stavropoulos Konstantinos and Kokkinos Peter, Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun, Current Pharmaceutical Design 2017; 23 (10) . https://dx.doi.org/10.2174/1381612823666170206154706

DOI https://dx.doi.org/10.2174/1381612823666170206154706	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286